FTH
Faeth Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$18.69Close
$23.6MMarket cap
$7.89 – $40.0552-week range
Nov 13, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 53% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 13, 2026, in 12 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
53%
1wk
up 9.4%
price change
1mo
down 37.2%
price change
12-month return
up 98%
market up 11% ·
its own up 89%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.3×
price / book
Earnings yield
down 149.5%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 74%
return on equity
Free cash margin
—
-$20.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
12.6%
$2.35 a day · 2×ATR $14.00
RS
77 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
1.3×
vs 50-day average
Up/down volume
0.62
50 sessions
Implied move
—
no option chain · report Nov 13, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
Last reported
Aug 4, 2026
Last shock
Jul 16, 2026-18% in one session4.0× volumeno filing matched-28% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$19.5M | -$37.5M | -$50.2M | -$37.1M | -$32.6M | -$22.3M |
| Net income | -$20.1M | -$36.8M | -$48.6M | -$34.1M | -$30.2M | -$21.1M |
| Earnings per share | — | -$26.56 | -$31.65 | -$24.40 | -$24.01 | -$16.72 |
| Free cash flow | -$18.9M | -$32.3M | -$39.3M | -$32.2M | -$24.8M | -$20.5M |
| Cash | $16.6M | $7.2M | $17.8M | $13.0M | $10.0M | $8.7M |
| Long-term debt | $567,000 | — | — | — | — | — |
| Shareholders' equity | -$56.4M | $146.5M | $103.4M | $64.9M | $38.4M | $18.6M |
| Shares outstanding | 93.77k | 1.53m | 1.54m | 1.25m | 1.26m | 1.26m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 15, 2026 | Quarterly ↗ | Mar 31, 2026 | 45d |
| Mar 30, 2026 | Annual ↗ | Dec 31, 2025 | 89d |
| Nov 14, 2025 | Quarterly ↗ | Sep 30, 2025 | 45d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Mar 28, 2025 | Annual ↗ | Dec 31, 2024 | 87d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Director or officer change ↗ |
| Sep 17, 2026 | Director or officer change ↗ |
| Aug 4, 2026 | Results ↗ |
| Jul 23, 2026 | Director or officer change ↗ |
| Jun 18, 2026 | Material agreement · Other events ↗ |
| Jun 15, 2026 | Agreement ended · Director or officer change · Charter or bylaws · Regulation FD · Other events ↗ |
| Jun 10, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| May 22, 2026 | Other events ↗ |
| May 21, 2026 | Other events ↗ |
| May 15, 2026 | Results ↗ |
| Apr 16, 2026 | Director or officer change ↗ |
| Mar 30, 2026 | Results ↗ |